Anxiolytic Research Articles

Effects of Inpatient Hospice Care on Cost and Medication Use in Patients with Lung Cancer: A Population-Based Retrospective Study in South Korea.

Background: Inpatient hospices (IHs) can alleviate distress and address economic burdens on patients with terminal cancer. However, there have been inconsistent findings regarding IHs in terms of cost savings and medication use. Objective: We aimed to examine cost savings associated with IHs, according to the timing of first hospitalization before death, and analyze their use of medication, among Korean patients with terminal lung cancer. Methods: Using the South Korean national health insurance claim database, we identified 31,139 patients with lung cancer who died between 2017 and 2020. Their daily hospitalization costs were analyzed using a generalized linear model stratified by time of first hospitalization before death. Medication use was examined using a negative binomial model. Results: IHs spent $134, and $21 less on patients during days 1-7, and 8-30 before death, but $18, $44, $36, and $54 more during days 31-60, 61-90, and 91-180, respectively, compared with non-IHs (all p < 0.05). However, total hospitalization costs in the year preceding death did not differ (relative risk: 0.990, 95% confidence interval [CI]: 0.972-1.007, p > 0.05). IHs used 2.103 times more opioid analgesics (95% CI: 1.980-2.233, p < 0.001). They also used more antiemetics, delirium medications, and antianxiety agents, as well as fewer antidepressive agents, systemic steroids, diuretics, total parenteral nutrition, and antibiotics (all p < 0.05). Conclusions: Patients with terminal lung cancer in IHs in Korea were more likely to receive symptom-oriented medications and experienced reduced hospitalization costs only during the 30 days preceding death.

Coffee&amp;apos;s Health Benefits for Human Diet

Coffee is the most popular beverage in the world and the most consumed caffeinated beverage after water and tea. It contains a combination of several chemical components that, with the health benefits, most consumers start the day with at least one cup of coffee after eating and end the working day with coffee. It is considered an important part of modern-day life because it has an alarming effect on the human brain. In contrast, different groups report. They face unequal health risks and are therefore reluctant to drink coffee, suggesting individual differences in coffee intolerance. The purpose of this study was to briefly summarize the health benefits and risks of coffee consumption. Most informative reports suggest that long-term consumption of coffee and decaffeinated coffee can reduce the risk of many diseases. Among them, it is used to improve our physical performance, burn fat, reduce the risk of stroke, liver, prostate and colorectal cancer by 20%, the risk of Parkinson&amp;apos;s disease by 25%. the risk of dementia and protect our mind, brighten our mood, help fight depression and minimize the risk of suicide by 50%. In addition, coffee drinkers have a lower risk of heart disease, with highly integrated DNA. It has also been reported that coffee consumption naturally lengthens sleep latency, decreases total sleep duration and efficiency, and worsens putative sleep functions. However, from the positive health perspective of coffee consumption, a recent study reveals that coffee consumption does not always provide protective benefits, since excessive consumption is associated with a negative impact or risk to our health. Some negative effects of coffee consumption on our health: reduces appetite, affects pregnant women, people with cholesterol, causes insomnia and restlessness, breast tissue cysts in women, digestive disorders related to incontinence and risk of headache In addition, it reduces the likelihood of fertility in women and men, causes allergies and abortions, violent heart contractions, anxiety, depression and the need for anti-anxiety drugs, inhibits the production of collagen in human skin, improves the hearing loss. it does not help with prolonged sleep deprivation, it interferes with ossification and may even lead to an increased risk of bone fracture. Finally, more recent studies have reported that the consumption of coffee is beneficial for our health when it is optimal, about four glasses on average. Further research will be crucial to clarify the health benefits and risks of coffee consumption.

Late-stage-functionalization of anti-depressant molecule buspirone.

Buspirone, a well-established anxiolytic agent, has gained attention for its potential role as an antidepressant, primarily due to its unique pharmacological profile and the ability to modulate serotonin receptors effectively. Late-stage functionalization is considered as a pivotal strategy in drug synthesis that enhances the therapeutic efficacy of existing molecules. This review summarizes various late-stage functionalization techniques applicable to Buspirone, including photocatalyzed, metal-catalyzed, and enzyme-catalyzed reactions.

Clinical Improvement of Patients With Complications of Exfoliativa Dermatitis: A Case Report

Exfoliative dermatitis or erythroderma is a severe skin inflammatory syndrome, characterized by erythema and desquamation more than 90% of the body surface area. Previous study shown erythroderma incidence was 83 people in 2011 to 2014. Incidence of erythroderma in Portugal 9.4 cases per year, with the predominance age of 41 to 61 years. The most common etiology of erythroderma is psoriasis and dermatitis. A woman Mrs. T, 55 years old, came to emergency room Rajawali Citra General Hospital Bantul on 5 September 2023 with complaints of abdominal pain, frequent vomit, cough and itchy and dry skin on the face, upper limbs and lower limbs. Patient has erythroderma medical history since a year ago. On dermatological examination, the facial showed patch erythema with scales on left suprasilia and nasales, the upper and lower limbs showed xerotic. This patient was diagnosed with erythroderma with improvements. Patient was treated with Loratadine 10 mg tablets once a day orally and Desoximethasone oint twice a day. Erythroderma treatment depends on its underlying disease. The main therapy is using petrolatum, emollient or low-potency topical steroid to maintaince skin barrier function and reduce inflammatory. Antihistamines can be used to relieve pruritus and as antianxiety agent. A well combination drugs therapy shows clinical improvement on erythroderma performance.

Involvement of Molecular Mechanism and Biological Activities of Pemirolast: A Therapeutic Review

: This review paper aims to investigate the therapeutic benefits of pemirolast across different medical conditions, including asthma, allergic rhinitis, cancer, conjunctivitis, etc. The prevalence of allergic conditions has risen in recent decades, primarily attributed to environmental factors. This paper explores the role of pemirolast in managing and mitigating these diseases, shedding light on its potential applications in the context of evolving environmental influences. : This review paper investigates the diverse biological activities exhibited by pemirolast, encompassing its roles as an antimicrobial, analgesic, antiviral, anti-inflammatory, antioxidant, antihistamine, mast cell stabilizer, anti-tubercular, anticancer, anti-asthmatic, anti-malarial, diuretic, antianxiety, and antifungal agent. The positive outcomes of pemirolast application in various diseases are highlighted, showcasing its potential across a spectrum of medical conditions. : The pharmacological impact of pemirolast extends to diverse inflammatory mediators, enzymes, and hormones associated with various diseases. Pemirolast demonstrates inhibitory effects on key elements such as eosinophil activation, histamine, leukotriene, IgE, mast cells, basophils, prostaglandin, interleukin, T-helper cells, macrophage T-cells, neutrophils, tryptase, T-lymphocytes, interferons I-III, Amyloid β (Aβ) peptide, dsRNA transcription, GABA, dopamine, serotonin, and norepinephrine. This comprehensive exploration underscores pemirolast inhibitory actions across disorders, emphasizing its potential therapeutic relevance in diverse pathological conditions. : This review paper illuminates pemirolast potassium's versatile biological and therapeutic applications across various diseases. The potential synergies of combining pemirolast with buspirone, ritanserin, theophylline, and capreomycin are explored, showcasing its ability to elicit beneficial responses in addressing diverse ailments.

Advances in neuroscience research and big data's analysis on anxiety disorder.

Anxiety disorder is a complex disease with the influence of environmental and genetic factors and multimolecular participation, and it is also one of the most common mental disorders. The causes of disorders are not clear but may include a variety of social, psychological, and biological factors. Therefore, neither genetics, neurobiology, nor neuroimaging can independently explain the pathological mechanism. By searching the Web of Science databases, Derwent Innovation Patent database, ClinicalTrials.gov database, and Cortellis database, we analyze the current situation of papers, patents, clinical trials, and drugs of anxiety disorder. Second, the existing literature was reviewed to summarize the neurophysiological mechanism, brain imaging, gene, anti-anxiety drugs, and other aspects of anxiety disorders. This article reviews the research status of anxiety disorders. The heterogeneity of the disease, lack of treatment effectiveness, and gaps in translational medicine still present barriers to further advancement. Thus, in-depth explorations of the underlying biological mechanisms of anxiety disorders, the detection and intervention of biological targets, and further developments based on existing intervention strategies will drive future research on anxiety disorders. This article is categorized under: Neuroscience > Clinical.

Phytochemical and pharmacological evaluation of bacopa monniera for anti – anxiety activity

Anxiety, a common emotional response to stress, involves numerous brain regions and neurotransmitters, including the amygdala, prefrontal cortex, and hippocampus, and is partially by genetic, environmental, and biological factors. This study evaluates Bacopa monnieri, a herb known in Ayurvedic medicine for its cognitive-enhancing and adaptogenic properties, as a potential anti-anxiety agent. The plant's ethanolic extract revealed a variety of phytochemicals, including alkaloids, flavonoids, and saponins. Acute toxicity studies indicated a high safety margin with an LD50 exceeding 2000 mg/kg body weight. The anti-anxiety effects were assessed using three established models. In the Elevated Plus-Maze Test, Bacopa monnieri significantly reduced anxiety levels in mice, comparable to the standard anxiolytic benzodiazepine. The Hole-Board Test showed increased head-dipping and rearing behaviors, while reducing immobility, suggesting anxiolytic activity. The Light-Dark Exploration Test demonstrated the herb's ability to decrease anxiety-related behaviors, including a reduction in rearing in dark compartments and increased exploration of light areas. These findings provide scientific validation for Bacopa monnieri's traditional use in treating anxiety and support its potential as an effective and safe anti-anxiety agent in managing central nervous system disorders.

Efficacy of Virtual Reality Distraction Technique for Anxiety and Pain Control in Knee Arthroscopy under Spinal Anesthesia. A Randomized Controlled Trial

Abstract Background Regional anesthesia (RA) allows surgery without impacting the patient’s level of consciousness. This avoids disadvantages related to general anesthesia, especially the maintenance of upper airway. Aim of the Work The proposed study aimed to compare the effect of using non- pharmacological methods, i.e., virtual reality, on anxiety level and satisfaction with that of the sedating effect of midazolam. Patients and Methods In this study we compare Efficacy of virtual reality distraction technique for anxiety and sedation in knee arthroscopy under spinal anaesthesia. The study is conducted in Anesthesiology Department, Faculty of medicine, Ain Shams University. The study period is 6 months. The sample size is 100 patients divided in two groups randomly (Group I and Group II). Each group has 50 patients. Results The results showed that the application of virtual reality as a complementary modality might help manage perioperative anxiety in a way that is safe, effective, time-efficient, and enjoyable similar to that of sedating effect of midazolam with an advantage of excluding the undesirable adverse effect of sedative drug. Conclusion Virtual Reality is effective for reducing the anxiety of patient perioperative and increasing satisfaction in a safe, effective, time- efficient, enjoyable, and maintained patient's level of consciousness, in addition to the fact that preoperative sedatives and antianxiety drugs often have adverse side effects and may prolong patient recovery and discharge.

Exploring the multifaceted therapeutic potentials of Brassaiopsis palmata (leaves) through in‐vitro and in‐vivo approaches

AbstractBrassaiopsis palmata, an androgynous tree from Araliaceae family, has been widely found in the Asian subcontinent, and reported to have potentiality against skin infection, and many therapeutic properties still unidentified. Here, our current investigation aims to discover the innovative pharmacological potentials of the methanol extract of B. palmata leaves (MEBPL) through in‐vivo and in‐vitro approaches. Several secondary metabolites were revealed throughout the qualitative phytochemical screening of the plant extracts. MEBPL exhibited strong radical scavenging properties (IC50 178.13 µg/mL) through the 2, 2‐diphenyl‐1‐picryhydrazyl (DPPH) assay, and through the quantitative (phenolic and flavonoid) assays with a moderate (LD50 153.14 µg/mL) toxic effect. In anti‐inflammatory screening, MEBPL showed significant dose dependent inhibitory activity; and the peak inhibition were found 78.01 ± 1.22% and 82.46 ± 1.52% at 1000 µg/mL concentration on hypotonic‐induce RBC hemolysis &amp; protein denaturation test respectively. Moreover, the plant extracts manifested moderate percentage of clot lysis (28.24 ± 2.50%) on the investigation of thrombolytic assay. The anti‐nociceptive activity of MEBPL was analyzed through acetic acid and formalin induce pain tests. Both 200 and 400 mg/kg dose of MEBPL exerted significant (p ˂ 0.001) dose depending depletion of acetic acid induced writhing and formalin stimulated licking test which indicated strong analgesic properties of plant extracts. In addition, the outcomes of anti‐depressant evaluation suggested that treatment with both 200 and 400 mg/kg doses showed potential dose depending activity on both FST and TST model. Furthermore, the plant extracts manifested dose dependent reduction of anxiety like behaviors in the rodent model. Particularly, mice administrated with 400 mg/kg dose of MEBPL significantly (p ˂ 0.05) enhanced the percentage of entries and time spent in the open arm in EPM, and also showed the highest amount of head dipping tendency in HBT. In contrast, the outcomes of this research suggest that B. palmata could be another source of antioxidant, cytotoxic, anti‐inflammatory, thrombolytic, anti‐nociceptive, anti‐depressant, and anxiolytic agents. Further research on the mechanisms underlying bioactivities is required.

A Complete Guide to Understand PMS (Pre-Menstrual Syndrome) in Women’s and its Effective Ayurvedic and Allopathic Treatment

Many women around the world are suffering from common physical discomfort just before their menstrual cycle. Symptoms may vary women to women which can be mild to severe such that it could affect their regular activities. Based on the diagnostic criteria, 2.5–3% of women of reproductive age have the severe form of PMS, while 40% of these women experience the moderate type. The symptoms seen were fluid retention, pain in pelvic region, mastalgia, psychological changes, behavioural changes, gastrointestinal problems, skin related problems and nervous system affecting problem. The targeting therapies to cure PMS includes allopathic as well as ayurvedic remedies. Allopathic includes mainly targeting brain SSRIs and some pharmacotherapies including administration of NSAIDs, anxiolytic agents, gonadotropin-releasing hormone (GnRH) agonists. etc. and recent studies shows combined oral contraceptives shows good effect to cure PMS prominently. And daily physical exercise can also overcome the PMS related problems wisely.

Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia

Introduction: Preclinical and clinical evidence has elucidated that cannabis-based medical formulations (CBMFs) may display anxiolytic, antidepressive, and neuroprotective properties. CBMFs are often considered as novel therapeutic anxiolytic agents that can be prescribed as pharmacotherapy for symptomatic domains in anxiety disorders (ADs). Our aim was to explore effectiveness and tolerability of enriched cannabidiol (CBD) oil extract formulations in adults with anxiety symptoms in an outpatient mental health program in Colombia during the COVID-19 pandemic. Methods: We conducted an observational, retrospective, real-world evidence case series from electronic health records at Zerenia Clinic in Bogotá, Colombia between June 2021 and December 2022. Our convenience sample consisted of people searching for CBMFs for the treatment of anxiety symptoms. A cohort of 24 adults was prescribed with enriched CBD in the form of non-sterile oral liquids suspended in sesame seed oil extracts for DSM-5 unspecified anxiety disorder and followed throughout the first year of treatment. CBMFs were prepared by dissolving full-spectrum cannabis extracts in sesame seed oil to a standardized concentration of active ingredients which is CBD-enriched. The oil extract contained 100 mg/mL of CBD and less than 1.9 mg/mL of THC. Primary outcome measures established were the anxiety subscale in the Hospital Anxiety and Depression Scale (HADS-A), and the clinical global impression scale with regard to severity (CGI-S) and improvement (CGI-I) at baseline, 6 months, and 12 months during follow-up. Secondary outcome measures established were HADS depression subscale (HADS-D) and the Epworth Sleepiness Scale (ESS), respectively. Participants also completed the patient-reported outcome measures (PROMs) during each visit throughout the 12-month follow-up. PROMs documented both participantʼs subjective improvement experience and progressive adverse effects. Results: After 6 months of treatment with sublingually administered enriched CBD oil extracts in a median dosage of 100 mg, more than half (54.17%) of the sample continued to report significant anxiety symptoms. After 12 months, only 37.50% persisted with significant anxiety symptoms with a median dose of 120 mg of enriched CBD oil extracts. Similar subjective improvements were reported with regard to sleep disturbances (SDs) as a secondary outcome. At baseline, less than half (46.83%) of the sample reported significant daytime sleepiness. After 6 months of enriched CBD oil extract treatment, less than one third (29.17%) continued to report SDs. At end point, a high proportion of the sample (87.50%) were considered to have normal daytime sleepiness. The cohort showed no clinically relevant depressive symptoms at baseline based on HADS-D scores; therefore, no improvement could be reported throughout the 12-month follow-up. Minimal gender differences with regard to HADS-D scores may be attributed to modifying effects of menopause-related symptoms. No significant adverse drug reactions or deaths were reported during the 12-month follow-up. Conclusions: Further research should determine the long-term efficacy, safety, and appropriate dosages of enriched CBD oil extracts in treating specific ADs rather than broad and unspecified anxiety symptoms. The state of the art of CBMFs for ADs should be warranted by future randomized controlled trials. The next stage for cannabis research should be focused in performing head-to-head trials comparing enriched CBD extracts or capsules versus first-line treatments proven to be effective in ADs.

Unveiling Niaprazine's Potential: Behavioral Insights into a Re-Emerging Anxiolytic Agent.

Ongoing global research actions seek to comprehensively understand the adverse impact of stress and anxiety on the physical and mental health of both human beings and animals. Niaprazine (NIA) is a chemical compound that belongs to the class of piperazine derivatives. This compound has recently gained renewed attention due to its potential therapeutic properties for treating certain conditions such as anxiety. Despite its potential benefits, the behavioral effects of NIA have not been thoroughly investigated. This study aimed to examine NIA's potential as an anti-anxiety and anti-stress agent. After administering either vehicle or NIA in their drinking water to mice for 14 days, we conducted behavioral analyses using the Marble Burying Test and the Elevated Plus Maze test. NIA-treated mice spend more time in the open arms and bury fewer marbles. Moreover, a stability study confirmed the linear relationship between NIA concentration and its response across concentrations encompassing the NIA mother solution and the NIA solutions administered to mice. Also, a preliminary synaptic toxicity analysis showed no direct damage to cortical nerve endings. Here, we show that NIA can modulate anxiety-related behaviors without significantly impacting exploratory activity or adverse effects. Our work describes new findings that contribute to the research on safer and more tolerable anxiety management options.

5,7,3',4',5'-Pentamethoxyflavone, a Flavonoid Monomer Extracted From Murraya paniculata (L.) Jack, Alleviates Anxiety Through the A2AR/Gephyrin/GABRA2 Pathway.

The sedative and hypnotic properties of 5,7,3',4',5'-pentamethoxyflavone (PMF), a monomer extracted from the leaves of Murraya paniculata (L.) Jack, have been reported. However, the role of PMFs in the development of anxiety remains uncertain. An anxiety model was developed using chronic unpredictable mild stimulation (CUMS). Kunming mice were randomly allocated to the following groups: control, CUMS, PMF (50 mg/kg), PMF (100 mg/kg), and diazepam (3 mg/kg). The anxiolytic effects of PMFs were evaluated using elevated plus maze (EPM) test and open field test (OFT). Enzyme-linked immunosorbent assay (ELISA) kits were used to analyze the serum levels of corticosterone (CORT), 5-hydroxytryptamine (5-HT), gamma-aminobutyric acid (GABA), and cyclic adenosine monophosphate (cAMP) in the hippocampus. High-throughput-16S rRNA sequencing was performed to investigate its effect on the composition of the gut microbiota. Subsequently, western blotting was performed to assess the expression of GABAergic synaptic-associated proteins. PMF effectively mitigated CUMS-induced anxiety-like behavior. Further examination revealed that PMF treatment ameliorated dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis and increased 5-HT and GABA levels in the hippocampus. Notably, the ability of PMF to maintain the stability of GABAergic synapses by enhancing the species composition of the gut microbiota and acting on the adenosine a2a receptor (A2AR)/gephyrin/gamma-aminobutyric acid A receptor alpha 2 (GABRA2) pathway revealed a previously unrecognized mechanism for the anxiolytic effect of PMF. These findings suggest that PMF enhances the expression of A2AR, preserves GABAergic synaptic stability, and reduces anxiety by modulating the microbiota composition. Thus, it holds promise as an anxiolytic agent.

A Systematic Review of Phenibut Withdrawals.

Phenibut is an anxiolytic agent that was originally used as a treatment for anxiety, depression, post-traumatic stress disorder (PTSD), and insomnia. It is a gamma-aminobutyric acid (GABA) mimetic, which stimulates GABA receptors in the brain. This increases the inhibitory effects of GABA leading to a greater chance of a sedative response and risk for abuse. It is not currently registered in Western countries but is easily accessible online as a supplement. This is a systematic review of case reports of phenibut patients with withdrawal symptoms published in the PubMed database between January 2010 and October 2023. Following the inclusion criteria application, 15 articles were included. Descriptive statistics were used to analyze the results. The average age of patients with phenibut withdrawals was 31.8 years (SD=12.66 years), and 13 cases (87%) were males. The average dosage was 13.6 g/day (SD=8 g), ranging from 1.5 to 28.5 g/day. Nine cases (60%) presented at an emergency department, and three cases (17%) were presented at a clinic setting facility. The most common history of patients who took phenibut was alcohol or drug abuse (73%). A history of anxiety and depression (60%) was also seen in the majority of patient presentations. Phenibut is never prescribed in the United States, and there are no official guidelines for phenibut use. Educating all physicians about the potentially harmful supplements available to patients and their biological mechanisms is essential. This review highlights the importance of collecting a thorough patient history, including supplements, to help prevent phenibut misuse and subsequent withdrawals.

Evaluating the Cognitive Impact of Anxiolytics on Elderly Patients: A prospective observational study.

Background: The cognitive effects of anxiolytics in older adults are an important domain to research given the high rates of anxiety disorders and these medications commonly prescribed. Benzodiazepines, and some of the newer non-benzo" sedative anxiolytic agents have been associated with cognitive effects as a potential side effect. This study is going to be conducted in Lady Reading Hospital (LRH) Peshawar; thus the data will reflect upon population served by this particular hospital. Objectives: To assess the cognitive impact of anxiolytic medication in geriatric patients, specifically on short-term memory (STM), attention and executive functions. Design: A observational study. Place and Duration of Study: Department of Pharmacy, Lady Reading Hospital-Peshawar starting from January 05th 2021 to July 05th ,2022. Methods: This was an observational study conducted on 150 elderly patients at Lady Reading Hospital through non probability sampling, comparing cognitive domain of functioning between 75 users and rest controls. Cognitive function was evaluated by Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment before and after the medication. Results - This section will describe the cognitive score changes in relation to anxiolytic use. One-way ANOVA will be utilized to examine the differences in cognitive outcomes according drug type, dosage and duration of use. Conclusions: The use of anxiolytics in elderly patients is associated with deterioration cognitive function, which was confirmed by a decrease MMSE and MoCA scores during the course of treatment. The potential cognitive side effects when prescribing anxiolytics to the elderly requires a nuanced approach by healthcare providers. Keywords: Anxiolytics; older adult patients; cognitive performance, MMSE/MoCA.

Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients

Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good drugs to alleviate the psychiatric problems among cancer patients. The recent reviews deal with the pharmacodynamics, pharmacokinetics and efficacy of psilocybin in the treatment of patients suffering from anxiety and depression.

The Swiss Prison Study (SWIPS): Results from a registry-based study of prisoners in Switzerland from 2015 to 2020.

The purpose of the present study was to evaluate demographic characteristics of inmates in the Canton of Zurich (exposure), and investigate the changes in diseases and drug use between 2015 and 2020 (outcome). The study prospectively evaluated 51,989 inmates admitted to the Police Prison Zurich in Switzerland between 1 April 2015 and 31 August 2020 and who were systematically medically assessed. A total of 19,027 (37%) inmates had one or more health conditions, which the authors recorded according to the International Classification of Diseases-10 (ICD-10), in addition to demographic data (country of origin, sex, age, year of imprisonment), as well as details of any drugs used (type and dosage). The 19,027 inmates with medical conditions had a mean age of 35.4±12.5 years (range 10-89) and comprised 16,489 males (87%). The inmates originated from 170 countries, including 4606 from Switzerland (24.2%), 4227 from Eastern Europe (22%) and 3432 from the Middle East & North Africa (18%). A total of 1631 inmates (9%) were enrolled in the medication-assisted treatment (MAT) programme, and 672 patients (4%) received a psychiatric evaluation. The proportions of foreign prisoners did not increase during the study period. There was a significant increase in the use of antipsychotics from year 1 to 5 (y = 0.866x; R2= 0.902; p = 0.01) and anticonvulsants from year 1 to 4 (y = 1.27x; R2= 0.823; p = 0.01), and a significant decrease in the use of analgesics from year 2 to 5 (y = -4.42x; R2= 0.947; p = 0.03) and antianxiety drugs from year 1 to 4 (y = -3.31x; R2= 0.989; p = 0.005). Inmates from Switzerland were most likely to use antianxiety drugs, while inmates from the Middle East & North Africa were most likely to use antipsychotics (OR 2.09; CI 1.88-2.34) and anticonvulsants (OR 3.52; CI 2.90-4.29), whereas inmates from Latin and North America were most likely to use herbal medicine (OR 1.50; CI 1.05-2.10). The findings of this study could help anticipate needs of prisons as well as improve treatment of disease and assist with substance use or abuse, particularly in the context of migration.

Comparing pharmacotherapy and transcranial magnetic stimulation for the treatment of anxiety and depression after aortic dissection surgery.

Aortic coarctation is a potentially fatal condition that is primarily treated surgically. Despite successful procedures, patients frequently experience postoperative anxiety and depression, which can hinder recovery and worsen outcomes. Pharmacological interventions, such as 5-hydroxytryptamine (5-HT) and norepinephrine reuptake inhibitors, are commonly prescribed; however, their efficacy alone or in combination with non-invasive brain stimulation techniques, such as repetitive transcranial magnetic stimulation (TMS), remains unclear. To assess the effect of medications and TMS on post-aortic surgery anxiety and depression. We analyzed the outcomes of 151 patients with anxiety and depression who were hospitalized for aortic dissection between January 2020 and September 2022. Using the random number table method, 75 and 76 patients were allocated to the normal control and study groups, respectively. All the patients were treated using routine procedures. The control group was administered anti-anxiety and anti-depression drugs, whereas the study group was treated with TMS in addition to these medications. The patients in both groups showed improvement after two courses of treatment. The Hamilton Anxiety Scale (HAMA) and the Hamilton Depression Scale (HAMD) were used to assess anxiety and depression, respectively. The serum levels of brain-derived neurotrophic factor (BDNF) and 5-HT were determined using enzyme-linked immunosorbent assay. The Pittsburgh Sleep Quality Index (PSQI) was used to estimate sleep quality, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to assess cognitive function. The HAMD and HAMA scores reduced in 2 groups, with the study group achieving a lower level than control (P < 0.05). In the control group, 43 patients recovered, 17 showed improvement, and 15 were deemed invalid. In the study group, 52 recovered, 20 improved, and four were invalid. The efficacy rate in study group was 94.74% compared to 80.00% in control (P < 0.05). The BDNF and 5-HT levels increased in both groups, with higher levels observed in the experimental group (P < 0.05). Moreover, the PSQI scores decreased in 2 groups, but were lower in the intervention group than control (P < 0.05). The scores of the RBANS items increased, with the study group scoring higher than control (P < 0.05). Combining anti-anxiety and anti-depressive drugs with repetitive TMS after aortic surgery may enhance mood and treatment outcomes, offering a promising clinical approach.

Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.

Newly conducted research suggests that metabolic disorders, like diabetes and obesity, play a significant role as risk factors for psychiatric disorders. This connection presents a potential avenue for creating novel antidepressant medications by repurposing drugs originally developed to address antidiabetic conditions. Earlier investigations have shown that GLP-1 (Glucagon-like Peptide-1) analogs exhibit neuroprotective qualities in various models of neurological diseases, encompassing conditions such as Alzheimer's disease, Parkinson's disease, and stroke. Moreover, GLP-1 analogs have demonstrated the capability to enhance neurogenesis, a process recognized for its significance in memory formation and the cognitive and emotional aspects of information processing. Nonetheless, whether semaglutide holds efficacy as both an antidepressant and anxiolytic agent remains uncertain. To address this, our study focused on a mouse model of depression linked to type 2 diabetes induced by a High Fat Diet (HFD). In this model, we administered semaglutide (0.05mg/Kg intraperitoneally) on a weekly basis to evaluate its potential as a therapeutic option for depression and anxiety. Diabetic mice had higher blood glucose, lipidic profile, and insulin resistance. Moreover, mice fed HFD showed higher serum interleukin (IL)-1β and lipopolysaccharide (LPS) associated with impaired humor and cognition. The analysis of behavioral responses revealed that the administration of semaglutide effectively mitigated depressive- and anxiety-like behaviors, concurrently demonstrating an enhancement in cognitive function. Additionally, semaglutide treatment protected synaptic plasticity and reversed the hippocampal neuroinflammation induced by HFD fed, improving activation of the insulin pathway, demonstrating the protective effects of semaglutide. We also found that semaglutide treatment decreased astrogliosis and microgliosis in the dentate gyrus region of the hippocampus. In addition, semaglutide prevented the DM2-induced impairments of pro-opiomelanocortin (POMC), and G-protein-coupled receptor 43 (GPR43) and simultaneously increased the NeuN + and Glucagon-like Peptide-1 receptor (GLP-1R+) neurons in the hippocampus. Our data also showed that semaglutide increased the serotonin (5-HT) and serotonin transporter (5-HTT) and glutamatergic receptors in the hippocampus. At last, semaglutide changed the gut microbiota profile (increasing Bacterioidetes, Bacteroides acidifaciens, and Blautia coccoides) and decreased leaky gut, improving the gut-brain axis. Taken together, semaglutide has the potential to act as a therapeutic tool for depression and anxiety.

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis.

The study aims to identify the drugs associated with drug withdrawal syndrome in the Food and Drug Administration Adverse Event Reporting System (FAERS) and estimate their risks of causing withdrawal syndrome. All the data were collected from FAERS from the first quarter of 2004 to the third quarter of 2023. Disproportionality analyses of odds ratio (ROR) and proportional reported ratio were conducted to identify potential adverse effects signal of drug withdrawal syndrome. A total of 94,370 reports related to withdrawal syndrome from the data. The top 50 drugs with most frequency reported were analyzed, and 29 exhibited a positive signal based on the number of reports. The top three categories of drugs with positive signals included opioids, antidepressant drugs and antianxiety drugs. Other classifications included opioid antagonist, muscle relaxant, antiepileptic drugs, analgesics, hypnotic sedative drugs and antipsychotic drugs. Our analysis of FAERS data yielded a comprehensive list of drugs associated with withdrawal syndrome. This information is vital for healthcare professionals, including doctors and pharmacists, as it aids in better recognition and management of withdrawal symptoms in patients undergoing treatment with these medications.